title: Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.
abstract: A solid phase extraction procedure (SPE) for 13 'new' antidepressants (venlafaxine, fluoxetine, viloxazine, fluvoxamine, mianserin, mirtazapine, melitracen, reboxetine, citalopram, maprotiline, sertraline, paroxetine and trazodone) together with eight of their metabolites (O-desmethylvenlafaxine, norfluoxetine, desmethylmianserine, desmethylmirtazapine, desmethylcitalopram, didesmethylcitalopram, desmethylsertraline and m-chlorophenylpiperazine) from plasma is optimized using HPLC-DAD as monitoring system. Special attention has been paid to the choice of washing and eluting solvent, resulting in a highly concentrated, clean and moisture free extract, also suitable for GC-MS. A total number of 10 sorbents (apolar, polymeric, ion-exchange and mixed mode) was evaluated. Based on recovery, reproducibility and absence of interfering substances the strong cation exchanger gave the best results. Recoveries were determined at low and high therapeutic and toxic levels and ranged between 70 and 109% for all compounds, except for trazodone (39%).
authors.affiliation: Laboratory of Toxicology, Ghent University, Faculty of Pharmaceutical Sciences, Harelbekestraat 72, B-9000 Ghent, Belgium.
authors.forename: Sarah M R
authors.initials: SM
authors.lastname: Wille
authors.forename: Kristof E
authors.initials: KE
authors.lastname: Maudens
authors.forename: Carlos H
authors.initials: CH
authors.lastname: Van Peteghem
authors.forename: Willy E E
authors.initials: WE
authors.lastname: Lambert
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000097:blood*; D000929:Antidepressive Agents, Tricyclic / Q000097:blood*; D015283:Citalopram / Q000031:analogs & derivatives / Q000097:blood; D003511:Cyclohexanols / Q000097:blood; D000069468:Desvenlafaxine Succinate; D005473:Fluoxetine / Q000031:analogs & derivatives / Q000097:blood; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods*; D006801:Humans; D008803:Mianserin / Q000031:analogs & derivatives / Q000097:blood; D008832:Microchemistry / Q000379:methods*; D000078785:Mirtazapine; D010879:Piperazines / Q000097:blood; D015203:Reproducibility of Results; D020280:Sertraline / Q000031:analogs & derivatives / Q000097:blood
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D003511:Cyclohexanols; D010879:Piperazines; D005473:Fluoxetine; D015283:Citalopram; D008803:Mianserin; C046304:desmethylcitalopram; C064735:didesmethylcitalopram; D000078785:Mirtazapine; C065162:desmethylsertraline; C036139:norfluoxetine; C056517:desmethylmianserin; D020280:Sertraline; C015068:1-(3-chlorophenyl)piperazine; D000069468:Desvenlafaxine Succinate